2076975 2077203
최종편집 2024-06-15 06:02 (토)
Ildong PharmaceuticalㆍSK Bioscience performed well amid stock market crash in November
상태바
Ildong PharmaceuticalㆍSK Bioscience performed well amid stock market crash in November
  • Hyeokgi Lee, Newsmp
  • 승인 2021.12.01 15:59
  • 댓글 0
이 기사를 공유합니다

37 out of 45 stocks fell in a month… 21 stocks saw a double-digit drop
Pharmaceutical index expanded as three bio companies aced…  Ildong Pharmaceuticalㆍ    SK Bioscience soared more than 20%

Pharmaceutical stocks are falling endlessly.

According to the Korea Exchange, 37 out of the 45 pharmaceutical stocks in the KOSPI market fell in November, and 21 of them recorded double-digit declines.

On the other hand, only 8 stocks rose during the same period, while only 3 stocks made double-digit growth.

Nevertheless, the index’s market capitalization rather expanded as the three major bio stocks, which account for nearly 80% of the pharmaceutical index’s market capitalization, rose en masse.

By stock, SK Bioscience’s stock price soared 22.0% despite the bearish market, the highest share price increase among 45 constituent stocks.

That of Ildong Pharmaceutical also jumped 21.4%, while Gene One Life Science also recorded a 17.8% rise, close to 20%.

Pharmicell rose 5.2%, Celltrion 3.2%, Samsung Biologics 2.1%, Korea United Pharmaceutical 0.4%, and Boryung Pharmaceutical 0.3%.

Contrarily, Shin Poong Pharmaceutical plunged 36.5%, the only one to drop over 30%. Reyon Pharmaceutical plummeted 28.3%, Myungmoon Pharmaceutical 23.3%, and Green Cross 20.6%.

In addition, Kukje Pharma, Samsung Pharmaceutical, Aprogen Pharmaceuticals, Kyongbo Pharmaceutical, Hyundai Pharmaceutical, Chong Kun Dang Holdings, CKD Bio, ORIENTBIO, Yuyu Pharma, JW Life Science, Kwang Dong Pharmaceutical, Yungjin Pharm., Handok, Dongsung Pharmaceutical, Jeil Pharmaceutical, and Hana Pharm recorded double-digit drops.

Il-Yang Pharmaceutical, Chong Kun Dang Pharmaceutical, JW Pharmaceutical, Bukwang Pharmaceutical, Ilsung Pharmaceutical, Dong Wha Pharmaceutical, Daewon Pharmaceutical, Whanin Pharmaceutical, HanAll Biopharma, Dong-A ST, Daewoong Pharmaceutical, and Samjin Pharmaceutical also fell more than 5%, and Hanmi Pharmaceutical, Yuhan Corporation, PharmGen Science, Il Dong Holdings ended November with sluggish stock prices compared to the end of the previous month.

Meanwhile, the market capitalization of 37 out of 45 constituent stocks dropped from October, but the market capitalization of the pharmaceutical index increased by KRW 2.6175 trillion from KRW 135.7384 trillion to KRW 138.22 trillion in a month as the market capitalization of three major bio shares led by SK Bioscience advanced.
In particular, SK Bioscience’s market capitalization increased by KRW 3.8633 trillion to KRW 21.4583 trillion, returning to the KRW 20 trillion mark.

Samsung Biologics was up by KRW 1.1 trillion over the same period, Celltrion by KRW 899.1 billion, and Gene One Life Science by more than KRW 200 billion.

However, Shin Poong Pharmaceutical’s market capitalization decreased by KRW 1.0014 trillion, Green Cross by KRW 660.3 billion, and Reyon Pharmaceutical by KRW 282.6 billion, while Yuhan Corporation, Hanmi Pharmaceutical, Chong Kun Dang Pharmaceutical, and Yungjin Pharmaceutical also fell by more than KRW 100 billion.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.